Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
AssigneeMemorial Sloan Kettering Cancer Center
InventorsEric Pamer, Peter McKenney, Silvia Caballero
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.
Claims21
A therapeutic composition comprising a Clostridiales VE202-05 bacteria and at least one of a Clostridium scindens bacteria, a Blautia producta bacteria, or both a Clostridium scindens bacteria and a Blautia producta bacteria.
Dependencies are inferred from the claim text.